Application of oncolytic virus in tumor therapy

被引：32

作者：

Huang, Zhijian ^{[1
]}

Guo, Hongen ^{[2
]}

Lin, Lin ^{[3
]}

Li, Shixiong ^{[1
]}

Yang, Yong ^{[4
]}

Han, Yuanyuan ^{[5
,8
]}

Huang, Weiwei ^{[3
,9
]}

Yang, Jialiang ^{[6
,7
,10
]}

机构：

[1] Fujian Med Univ, Fujian Canc Hosp, Dept Breast Surg Oncol, Clin Oncol Sch, Fuzhou, Peoples R China

[2] Dermatol Hosp Fuzhou, Dept Dermatol, Fuzhou, Fujian, Peoples R China

[3] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China

[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Liver Ctr, Boston, MA USA

[5] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Ctr Tree Shrew Germplasm Resources, Kunming, Peoples R China

[6] Geneis Beijing Co Ltd, Beijing, Peoples R China

[7] Changsha Med Univ, Acad Workstat, Changsha, Peoples R China

[8] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Peoples R China

[9] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou 350014, Peoples R China

[10] Geneis Beijing Co Ltd, Beijing 100102, Peoples R China

来源：

JOURNAL OF MEDICAL VIROLOGY | 2023年 / 95卷 / 04期

关键词：

combined therapy; genetic engineering; immunotherapy; oncolytic virus; tumor treatment; NEWCASTLE-DISEASE VIRUS; IMMUNOGENIC CELL-DEATH; HUMAN ADENOVIRUS; INTERFERON-BETA; CANCER-THERAPY; T-CELLS; IMMUNOTHERAPY; EXPRESSION; GENE; CYTOKINES;

D O I：

10.1002/jmv.28729

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well as activate the innate and adaptive immune systems in patients. Thus, they have been considered as a promising measure for safe and effective cancer treatment. Recently, a few genetically engineered OVs have been developed to further improve the effect of tumor elimination by expressing specific immune regulatory factors and thus enhance the body's antitumor immunity. In addition, the combined therapies of OVs and other immunotherapies have been applied in clinical. Although there are many studies on this hot topic, a comprehensive review is missing on illustrating the mechanisms of tumor clearance by OVs and how to modify engineered OVs to further enhance their antitumor effects. In this study, we provided a review on the mechanisms of immune regulatory factors in OVs. In addition, we reviewed the combined therapies of OVs with other therapies including radiotherapy and CAR-T or TCR-T cell therapy. The review is useful in further generalize the usage of OV in cancer treatment.

引用

页数：12

共 154 条

[1] Targeting immunogenic cell death in cancer [J].

Ahmed, Asma ;

Tait, Stephen W. G. .

MOLECULAR ONCOLOGY, 2020, 14 (12) :2994-3006

[2] The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma [J].

Ali, Sahra ;

Kjeken, Rune ;

Niederlaender, Christiane ;

Markey, Greg ;

Saunders, Therese S. ;

Opsata, Mona ;

Moltu, Kristine ;

Bremnes, Bjorn ;

Gronevik, Eirik ;

Muusse, Martine ;

Hakonsen, Gro D. ;

Skibeli, Venke ;

Kalland, Maria Elisabeth ;

Wang, Ingrid ;

Buajordet, Ingebjorg ;

Urbaniak, Ania ;

Johnston, John ;

Rantell, Khadija ;

Kerwash, Essam ;

Schuessler-Lenz, Martina ;

Salmonson, Tomas ;

Bergh, Jonas ;

Gisselbrecht, Christian ;

Tzogani, Kyriaki ;

Papadouli, Irene ;

Pignatti, Francesco .

ONCOLOGIST, 2020, 25 (02) :E321-E327

[3]

Amedei A, 2013, RECENT PAT ANTI-CANC, V8, P126

[4] Oncolytic reovirus induces ovarian cancer cell apoptosis in a TLR3-dependent manner [J].

An, Yuanyuan ;

Wang, Xianyao ;

Wu, Xuxian ;

Chen, Liang ;

Yang, Yichen ;

Lin, Xiaojin ;

Wang, Nianxue ;

Duan, Jiangyao ;

Long, Shiqi ;

Zhao, Xing .

VIRUS RESEARCH, 2021, 301

[5] interleukin-2: Biology, Design and Application [J].

Arenas-Ramirez, Natalia ;

Woytschak, Janine ;

Boyman, Onur .

TRENDS IN IMMUNOLOGY, 2015, 36 (12) :763-777

[6] Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles [J].

Autio, Karoliina ;

Knuuttila, Anna ;

Kipar, Anja ;

Pesonen, Sari ;

Guse, Kilian ;

Parviainen, Suvi ;

Rajamaki, Minna ;

Laitinen-Vapaavuori, Outi ;

Vaha-Koskela, Markus ;

Kanerva, Anna ;

Hemminki, Akseli .

MOLECULAR THERAPY-ONCOLYTICS, 2014, 1 :14002

[7] Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists [J].

Backhaus, Paul S. ;

Veinalde, Ruta ;

Hartmann, Laura ;

Dunder, Jessica E. ;

Jeworowski, Lara M. ;

Albert, Jessica ;

Hoyler, Birgit ;

Poth, Tanja ;

Jaeger, Dirk ;

Ungerechts, Guy ;

Engeland, Christine E. .

VIRUSES-BASEL, 2019, 11 (10)

[8] Updates to the antitumor mechanism of oncolytic virus [J].

Bai, Yang ;

Hui, Peng ;

Du, Xiaoyu ;

Su, Xing .

THORACIC CANCER, 2019, 10 (05) :1031-1035

[9] Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy [J].

Ban, Weiyue ;

Guan, Jianhuan ;

Huang, Hanwei ;

He, Zhonggui ;

Sun, Mengchi ;

Liu, Funan ;

Sun, Jin .

NANO RESEARCH, 2022, 15 (05) :4137-4153

[10] Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma [J].

Bommareddy, Praveen K. ;

Zloza, Andrew ;

Rabkin, Samuel D. ;

Kaufman, Howard L. .

ONCOIMMUNOLOGY, 2019, 8 (07)

← 1 2 3 4 5 6 7 8 9 10 →